Moors & Cabot, Inc. Cellectis S.A. Transaction History
Moors & Cabot, Inc.
- $2.17 Billion
- Q3 2025
Shares
1 transactions
Others Institutions Holding CLLS
# of Institutions
33Shares Held
9.71MCall Options Held
52.8KPut Options Held
0-
Long Focus Capital Management, LLC San Juan, PR4.12MShares$16.2 Million0.43% of portfolio
-
B Group, Inc. Dallas, TX3.28MShares$12.9 Million6.88% of portfolio
-
Credit Suisse Ag Zurich, V81.44MShares$5.67 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C3227KShares$893,8870.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il222KShares$874,5180.0% of portfolio
About Cellectis S.A.
- Ticker CLLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,510,800
- Market Cap $179M
- Description
- Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...